2021
Renal Denervation for Hypertension A Systematic Review and Meta-Analysis of Randomized, Blinded, Placebo-Controlled Trials
Ahmad Y, Francis D, Bhatt D, Howard J. Renal Denervation for Hypertension A Systematic Review and Meta-Analysis of Randomized, Blinded, Placebo-Controlled Trials. JACC Cardiovascular Interventions 2021, 14: 2614-2624. PMID: 34743900, DOI: 10.1016/j.jcin.2021.09.020.Peer-Reviewed Original ResearchConceptsPlacebo-controlled trialRenal denervationAntihypertensive medicationsBlood pressureMeta-analysisCatheter-based renal sympathetic denervationEffect of renal denervationRandomized placebo-controlled trialDrug-resistant hypertensionConcomitant antihypertensive medicationOffice blood pressureRenal sympathetic denervationAmbulatory systolic blood pressureRandom-effects meta-analysisSystolic blood pressureEffects of denervationAntihypertensive medication useMagnitude of benefitOffice systolicPlacebo-controlledEfficacy outcomesSympathetic denervationAntihypertensive agentsAmbulatory systolicEligible trialsTCT-452 Renal Denervation for the Treatment of Hypertension: A Systematic Review and Meta-Analysis of Randomized, Blinded, Placebo-Controlled Trials
Ahmad Y, Francis D, Bhatt D, Howard J. TCT-452 Renal Denervation for the Treatment of Hypertension: A Systematic Review and Meta-Analysis of Randomized, Blinded, Placebo-Controlled Trials. Journal Of The American College Of Cardiology 2021, 78: b186. DOI: 10.1016/j.jacc.2021.09.1305.Peer-Reviewed Original ResearchRandomized Blinded Placebo-Controlled Trials of Renal Sympathetic Denervation for Hypertension: A Meta-Analysis
Ahmad Y, Kane C, Arnold AD, Cook CM, Keene D, Shun-Shin M, Cole G, Al-Lamee R, Francis DP, Howard JP. Randomized Blinded Placebo-Controlled Trials of Renal Sympathetic Denervation for Hypertension: A Meta-Analysis. Cardiovascular Revascularization Medicine 2021, 34: 112-118. PMID: 33551282, PMCID: PMC8813172, DOI: 10.1016/j.carrev.2021.01.031.Peer-Reviewed Original ResearchConceptsRenal denervationRelative risk reductionBlood pressureCatheter-based renal denervationMajor adverse cardiac eventsPlacebo-controlled trial dataAmbulatory diastolic blood pressureAmbulatory systolic blood pressurePlacebo-controlled randomized trialSystolic blood pressure changesOffice diastolic pressureRandomized blinded placeboAdverse cardiac eventsOffice blood pressurePlacebo-controlled trialPrimary efficacy outcomeDiastolic blood pressureRenal sympathetic denervationSystolic blood pressureBlood pressure changesRisk reductionCause mortalityEfficacy outcomesSympathetic denervationAdverse events
2018
Fractional Flow Reserve and Instantaneous Wave-Free Ratio as Predictors of the Placebo-Controlled Response to Percutaneous Coronary Intervention in Stable Single-Vessel Coronary Artery Disease: Physiology-Stratified Analysis of ORBITA
Al-Lamee R, Howard JP, Shun-Shin MJ, Thompson D, Dehbi HM, Sen S, Nijjer S, Petraco R, Davies J, Keeble T, Tang K, Malik IS, Cook C, Ahmad Y, Sharp ASP, Gerber R, Baker C, Kaprielian R, Talwar S, Assomull R, Cole G, Keenan NG, Kanaganayagam G, Sehmi J, Wensel R, Harrell FE, Mayet J, Thom SA, Davies JE, Francis DP. Fractional Flow Reserve and Instantaneous Wave-Free Ratio as Predictors of the Placebo-Controlled Response to Percutaneous Coronary Intervention in Stable Single-Vessel Coronary Artery Disease: Physiology-Stratified Analysis of ORBITA. Circulation 2018, 138: circulationaha.118.033801. PMID: 29789302, DOI: 10.1161/circulationaha.118.033801.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-1 Receptor AgonistsAgedAngina, StableCardiac CatheterizationCoronary AngiographyCoronary Artery DiseaseCoronary StenosisDobutamineEchocardiography, StressExercise TestExercise ToleranceFemaleFractional Flow Reserve, MyocardialHealth StatusHumansMaleMiddle AgedPercutaneous Coronary InterventionPredictive Value of TestsProgression-Free SurvivalQuality of LifeRecovery of FunctionSeverity of Illness IndexTime FactorsUnited KingdomConceptsPercutaneous coronary interventionInstantaneous wave-free ratioFractional flow reserveSingle-vessel coronary artery diseaseTreadmill exercise timeCoronary artery diseaseExercise timeEchocardiography scoreStable anginaCoronary interventionArtery diseaseFlow reserveCanadian Cardiovascular Society class IIEffect of PCISevere single-vessel diseaseSingle-vessel coronary diseaseMean fractional flow reserveAngina frequency scorePlacebo-controlled effectsPlacebo-controlled efficacyPlacebo-controlled trialTotal exercise timeSingle-vessel diseaseAngina severityEchocardiographic improvement